Saturday, October 6, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall
Tracks: Adult ID, Investigative ID, Pediatric ID
Presentations:
A Host-response Assay Distinguishes Between Simple Influenza Patients and Influenza Patients with Bacterial Coinfection
Meital Paz, BSc;
Kfir Oved, PhD;
Tanya Gottlieb, PhD;
Asi Cohen, PhD;
Roy Navon, MSc;
Niv Mastboim, BSc;
Ellen Bamberger, MD;
Tom Friedman, MD;
Liat Etshtein, MD;
Olga Boico, PhD;
Isaac Srugo, MD;
Irina Chistyakov, MD;
Adi Klein, MD;
Israel Potasman, MD, FIDSA;
Eran Eden, PhD;
Liran Shani, MD
Prevention of Recurrent Clostridium difficile at Six Months following Treatment with Microbiota-based Therapy RBX2660: Durability Results from a Phase 2 Open-Label Study
Sarah Mische, PhD;
Robert Orenstein, DO, FIDSA;
Erik R. Dubberke, MD, MSPH, FIDSA, FSHEA;
Sahil Khanna, MBBS, MS;
Gail Hecht, MD;
Herbert Dupont, MD, FIDSA;
Christine Lee, MD, FRCPC;
Ken Blount, PhD
Nephrotoxicity associated with imipenem/cilastatin/relebactam (IMI/REL) versus imipenem/cilastatin plus colistin (IMI+CST) in patients with imipenem-nonsusceptible (NS) bacterial infections
Michelle Brown, RN;
Johann Motsch, MD;
Keith Kaye, MD, MPH;
Thomas File, MD;
Helen W. Boucher, MD, FIDSA;
Neika Vendetti, MPH;
Angela Aggrey, PhD;
Hee-Koung Joeng, PhD;
Robert Tipping, MS;
Jiejun Du, PhD;
Daryl D. Depestel, PharmD, BCPS-ID;
Joan Butterton, MD;
Nicholas A. Kartsonis, MD;
Amanda Paschke, MD, MSCE
Evaluation of Relapse and Reinfection Using Whole-Genome Sequencing of Clostridium difficile Isolates from Elderly Patients with C. difficile Infection (CDI) in the EXTEND Randomised, Controlled, Comparative Study of Extended-Pulsed Fidaxomicin and Vancomycin for the Treatment of CDI
Mark Wilcox, MD;
Oliver A. Cornely, MD;
Benoit Guery, MD;
Chris Longshaw, PhD;
Areti Georgopali, MD;
Andreas Karas, MD;
Gbenga Kazeem, PhD;
Jose Alejandro Palacios-Fabrega, PhD;
Maria J. G. T. Vehreschild, MD
Comparative Effectiveness Of High- Versus Standard-dose Influenza Vaccine On Hospitalization For Acute Myocardial Infarction In Nursing-home Residents: A Post-hoc Analysis From A Large Cluster-randomized Trial.
Elie Saade, MD, MPH;
Nina Joyce, PhD;
Jessica Ogarek, MS;
H. Edward Davidson, PharmD, MPH;
Lisa Han, MPH;
David Canaday, MD;
Abul Yasin, MD;
Theresa Shireman, PhD;
Vincent Mor, PhD;
Stefan Gravenstein, MD, MPH
A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants ≤3 Months of Age
Jason Kim, MD, MSCE;
Firdose Lambey Nakwa, MBBCh, FCPaeds, MMed Paeds;
Fábio De Araujo Motta, MD, PhD;
Perla Salcedo Lozada, MD;
Derya Alabaz, MD;
Hong Liu, MS;
Keisha Bloise, MS;
Mary Beth Dorr, PhD;
Leah J. Anderson Gaffney, PhD;
Nicholas Kartsonis, MD
Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
Tomas Mrkvan, PhD, MSc;
Laura Campora, MD;
Grégory Catteau, MSc;
Martine Douha, MSc;
Katrijn Grupping, PhD;
Caroline Herve, PhD;
George Kalema, PhD;
Thomas Heineman, MD, PhD;
Nicola P. Klein, MD, PhD;
Himal Lal, MD;
Lidia Oostvogels, MD;
Anne Schuind, MD
Pharmacist Prescribing and Care in Patients with Uncomplicated Urinary Tract Infections in the Community: Efficacy and Safety Outcomes of the RxOUTMAP Study
Nathan Beahm, BSP, PharmD;
Daniel Smyth, MD, FRCPC;
Ross Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC, FCAHS
Antiviral Effects, Pharmacokinetics (PK) and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants with Bronchiolitis, in the Phase 1b Study 53718678RSV1005
Federico Martinon-Torres, MD, PhD, Assoc Prof;
Sarah Rusch, MSc;
Dymphy Huntjens, PhD;
Bart Remmerie, Chem Eng;
Johan Vingerhoets, PhD;
Katie McFadyen, MPH;
Fernando Ferrero, Md, PhD;
Eugenio Baraldi, MD, FCCP;
Pablo Rojo Conejo, MD, PhD;
Cristina Epalza, MD;
Marita Stevens, MD
Ceftriaxone-Sulbactam-EDTA (CSE) vs. Meropenem (MR) in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes in Patients Infected with Ceftriaxone Non-Susceptible, Extended Spectrum Beta-Lactamase and Multi-Drug Resistant Pathogens at Baseline
Mohd Amin Mir, MS, MSc, PGDPM;
Saransh Chaudhary, BSc (Hons);
Kim Jacob Mammen, MCh (Urology);
Rajeev Sood, MCh (Urology);
P.N. Dogra, MCh (Urology);
Sudhir Chadha, MCh (Urology);
Ravimohan Mavuduru, MCh (Urology);
Rahul Janak Sinha, MCh (Urology);
Manu Chaudhary, PhD;
Gazalla Shiekh, PhD
Antibiotic Challenge Dose Testing Improves Patient Care and Lowers Costs in a Community Hospital: a Two-year Prospective Study
Barbara Lambl, MD MPH;
Samira Reyes-Dassum, MD;
Vinit Oommen, MD;
Oluchi Dike, MD;
Monique Freeley, RPh;
Darci Finocchiaro, MD;
Japheth Mukaya, MD;
AnaMaria Bensaci, MD MPH;
Johanna O'Connor, MD;
Kimberly G. Blumenthal, MD, MSc
A Randomized Controlled Trial of the Effect of Accelerated Copper Textiles on Healthcare-Associated Infections and Multidrug-Resistant Organisms: The “Investigating Microbial Pathogen Activity of Copper Textiles” (IMPACT) Study
Ebbing Lautenbach, MD, MPH, MSCE, FIDSA, FSHEA;
David Pegues, MD, FIDSA, FSHEA;
Barry Fuchs, MD;
Niels Martin, MD;
Irving Nachamkin, DrPH, MPH;
Warren Bilker, PhD;
Pam Tolomeo, MPH;
Leigh Cressman, MA;
Jacqueline Omorgobe, BS;
Kristen Johnson, BS;
Jennifer Han, MD, MSCE
TRAIL level and ImmunoXpert™ score complement molecular viral detection in the classification of febrile children – an interim analysis from the AutoPilotDx-study
Tobias Tenenbaum, MD;
Cihan Papan, MD;
Marian Porwoll, Student;
Ummaya Hakim, Medical Technician;
Alberto Argentiero, MD;
Ilaria Testa, MD;
Maria Bruna Pasticci, MD;
Daniele Mezzetti, MD;
Katia Perruccio, MD;
Liat Etshtein, MD;
Niv Mastboim, BSc;
Asi Cohen, PhD;
Einav Simon, PhD;
Olga Boico, PhD;
Liran Shani, MD;
Tanya Gottlieb, PhD;
Roy Navon, MSc;
Kfir Oved, PhD;
Eran Eden, PhD;
Arne Simon, MD;
Johannes Liese, MD;
Markus Knuf, MD;
Sven Schneider, MD;
Edoardo Farinelli, MD;
Susanna Esposito, MD
Microbiological Outcomes with Plazomicin (PLZ) versus Colistin (CST) in Patients (pts) with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE) in the CARE Study
Alisa W. Serio, PhD;
Alex Smith, MS;
Kevin M. Krause, MBA;
Irene Galani, PhD;
Ana Cristina Gales, MD, PhD;
Adrian Jubb, MBChB, PhD, FRCPath;
Lynn E. Connolly, MD, PhD
Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials
Jurgen K Rockstroh, MD;
Sanjay R Bhagani, MD;
Chloe Orkin, MBBCh;
Ruth Soto-Malave, MD;
Karine Lacombe, MD, PhD;
Zhenzhen Zhang, PhD;
Stanley Wang, MD, PhD;
Federico Mensa, MD;
Roger Trinh, MD, MPH
Procalcitonin-guided antibiotic therapy for lower respiratory tract infections in a US academic medical center
Jennifer Townsend, MD;
Victoria Adams-Sommer, PharmD;
Panagis Galiatsatos, MD;
David Pearse, MD;
Flora Kisuule, MD;
Hardin Pantle, MD;
Mary Masterson, PA-C;
Catherine Kiruthi, PharmD;
Paul Ortiz, PharmD;
Elsen Jacob, PharmD;
Jacob Sama, MD;
Michael Melgar, MD;
Seema Nayak, MD;
Jillian Irwin, MD;
Cyrus Mazidi, MD;
Sam Stern, MD;
Albert Agbanlog, RN;
Robert Jurao, RN;
Kevin Psoter, PhD, MPA;
Robin McKenzie, MD
Phase 1 Clinical Trial of Intranasal Immunization with M2-deficient, Single Replication, Live Influenza Vaccine (M2SR): Safety and Immune Response in Adults
Joseph Eiden, MD, PhD;
Gilad Gordon, MD;
Carlos Fierro, MD;
Robert Belshe, MD;
Harry Greenberg, MD, FIDSA;
Dan Hoft, MD, PhD;
Yasuko Hatta, DVM, PhD;
Michael Imboden, PhD;
Mike Moser, PhD;
Renee Herber, BS;
David Boltz, PhD;
Magdalena Tary-Lehmann, MD, PhD;
Yoshihiro Kawaoka, DVM, PhD;
Gabriele Neumann, PhD;
Paul Radspinner, MBA;
Roger Aitchison, ScM;
Pamuk Bilsel, PhD
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of a Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in Healthy Subjects
Antonios Aliprantis, MD, PhD;
Dennis Wolford, MS;
Luzelena Caro, PhD;
Brian Maas, PharmD;
Hua Ma, PhD;
Kalpit Vora, PhD;
Dong Geng, PhD;
Radha Railkar, PhD;
Andrew Lee, MD;
Laura Sterling, MD, MPH;
Eseng Lai, MD, PhD
Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared to PCV-13 in Healthy Older Adults Previously Vaccinated with 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
Ulrike Buchwald, MD;
James Peterson, MD;
Helen Stacey, MD;
Katie Julien, MD;
Tina Sterling, BSN;
Melanie Bruch, MD;
Gretchen Tamms, BS;
Jianing Li, PhD;
Alison Pedley, PhD;
Katrina Nolan, MD;
Patrice Benner, MD;
Chitrananda Abeygunawardana, MD;
Michael Winters, PhD;
Michael Kosinski, PhD;
Jon Stek, BS;
Luwy Musey, MD
Ceftriaxone-Sulbactam-EDTA vs. Meropenem in PLEA (a Phase 3, Randomized, Double-blind Trial): Outcomes by Baseline MIC in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis
Pankaj Mandale, MBBS, MPH;
Mohd Amin Mir, MS, MSc, PGDPM;
Saransh Chaudhary, BSc (Hons);
Manu Chaudhary, PhD;
Rajeev Sood, MCh (Urology);
N. S Patil, MD (Microbiology);
Salil Narang, MD (Pathology);
Anurag Pyasi, PhD;
Mohammad Shameem, MD, FRCP
Time to Viral Suppression does not Impact SVR in Patients Treated with Glecaprevir/Pibrentasvir for 8 Weeks
Christoph Sarrazin, MD;
Tram Tran, MD;
Douglas Dylla, Ph.D.;
Jordan J. Feld, MD, MPH;
Sanjeev Arora, MD;
David Victor III, MD;
Yiran B Hu, PhD;
Stanley Wang, MD, PhD;
Federico Mensa, MD;
David L. Wyles, MD
Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry
Jens Reimer, MD;
Albrecht Stoehr, MD;
Uwe Naumann, MD;
Gerlinde Teuber, MD;
Carsten Zamani, MD;
Stefan Mauss, MD;
Nazifa Qurishi, MD;
Kristina Lohmann, PhD;
Henning Kleine, PhD;
Andreas Pangerl, MD;
Stefan Christensen, MD
Multiplex PCR-Based Analysis of Enteric Pathogens in Faecal Samples from Patients with Clostridium difficile Infection in the Randomised, Controlled EXTEND Study Comparing the Efficacy of Extended-Pulsed Fidaxomicin with Vancomycin Therapy
Mark Wilcox, MD;
Oliver A. Cornely, MD;
Benoit Guery, MD;
Christopher Longshaw, PhD;
Areti Georgopali, MD;
Andreas Karas, MD;
Gbenga Kazeem, PhD;
Jose Alejandro Palacios-Fabrega, PhD;
Maria J. G. T. Vehreschild, MD
Ceftriaxone-Sulbactam-EDTA vs. Meropenem: Analysis of failed patients with assessment of MIC increases and changes in genotypic profile in PLEA (a Phase 3, Randomized, Double-blind Clinical Trial in Adults with Complicated Urinary Tract Infections or Acute Pyelonephritis)
Mohd Amin Mir, MS, MSc, PGDPM;
Saransh Chaudhary, BSc (Hons);
Manu Chaudhary, PhD;
Anurag Pyasi, PhD;
N. S Patil, MD (Microbiology);
Ruchi Girotra, DNB (Microbiology);
Salil Narang, MD (Pathology);
Nazish Fatima, MD (Microbiology)
CME Credits: Maximum of 0.00 hours of
AMA PRA Category 1 Credit™